Literature DB >> 2787228

Induction of articular cartilage degradation by recombinant interleukin 1 alpha and 1 beta.

R L Smith1, A C Allison, D J Schurman.   

Abstract

The purpose of this study was to compare the effects of human recombinant interleukin 1, alpha and beta, on articular cartilage. The effects of rIL-1 alpha and rIL-1 beta on proteoglycan degradation and synthesis following treatment of bovine articular cartilage in serum-free organ culture were quantified. Purified human IL-1 and both rIL-1 alpha and rIL-1 beta induced a two-fold or greater increase in glycosaminoglycan (GAG) release from cultured articular cartilage. Levels or rIL-1 alpha as low as 15 pM induced increased proteoglycan degradation whereas identical levels of rIL-1 beta did not. Killing of the cartilage cells abolished induced GAG release by all forms of IL-1. Analysis of proteoglycan size following IL-1 treatment showed limited degradation of material released into the culture medium or remaining within cartilage. Both forms of recombinant IL-1 inhibited GAG synthesis when continually present in the culture medium. Actinomycin D and cycloheximide inhibited IL-1 dependent cartilage destruction whereas indomethacin did not.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2787228     DOI: 10.3109/03008208909019079

Source DB:  PubMed          Journal:  Connect Tissue Res        ISSN: 0300-8207            Impact factor:   3.417


  9 in total

1.  N-terminal sequence of proteoglycan fragments isolated from medium of interleukin-1-treated articular-cartilage cultures. Putative site(s) of enzymic cleavage.

Authors:  P Loulakis; A Shrikhande; G Davis; C A Maniglia
Journal:  Biochem J       Date:  1992-06-01       Impact factor: 3.857

2.  Immunohistological identification of interleukin-1 activated chondrocytes.

Authors:  J T Dingle; M E Davies; B Y Mativi; H F Middleton
Journal:  Ann Rheum Dis       Date:  1990-11       Impact factor: 19.103

3.  Rare septic arthritis of the wrist and carpus primary osteoarticular manifestation of Mycobacterium tuberculosis: A case report.

Authors:  Nathan R Angerett; Zhongming Chen; Joseph J Kromka; Anna E Muzio; Michael E Kahan; John V Ingari; Robert J Maurer
Journal:  SAGE Open Med Case Rep       Date:  2022-05-21

4.  Cytokine profile of autologous conditioned serum for treatment of osteoarthritis, in vitro effects on cartilage metabolism and intra-articular levels after injection.

Authors:  Marijn Rutgers; Daniël B F Saris; Wouter J A Dhert; Laura B Creemers
Journal:  Arthritis Res Ther       Date:  2010-06-10       Impact factor: 5.156

5.  Regulation of collagenase gene expression by IL-1 beta requires transcriptional and post-transcriptional mechanisms.

Authors:  M P Vincenti; C I Coon; O Lee; C E Brinckerhoff
Journal:  Nucleic Acids Res       Date:  1994-11-11       Impact factor: 16.971

6.  Detection of cytokine activated chondrocytes in arthritic joints from pigs infected with Erysipelothrix rhusiopathiae.

Authors:  M E Davies; A Horner; B Franz; H J Schuberth
Journal:  Ann Rheum Dis       Date:  1992-08       Impact factor: 19.103

7.  Comparison of marker gene expression in chondrocytes from patients receiving autologous chondrocyte transplantation versus osteoarthritis patients.

Authors:  Reinout Stoop; Dirk Albrecht; Christoph Gaissmaier; Jürgen Fritz; Tino Felka; Maximilian Rudert; Wilhelm K Aicher
Journal:  Arthritis Res Ther       Date:  2007       Impact factor: 5.156

8.  Needle-knife therapy improves the clinical symptoms of knee osteoarthritis by inhibiting the expression of inflammatory cytokines.

Authors:  Munan Lin; Xihai Li; Wenna Liang; Jianhua Liu; Jianhong Guo; Jingxiong Zheng; Xianxiang Liu
Journal:  Exp Ther Med       Date:  2014-01-30       Impact factor: 2.447

9.  Efficacy and Safety of Miniscalpel Acupuncture on Knee Osteoarthritis: - A randomized controlled pilot trial.

Authors:  Seungah Jun; Jung Hee Lee; Han Mi Gong; Seong Hun Choi; Min Hwang Bo; Mi Suk Kang; Geon-Mok Lee; Hyun-Jong Lee; Jae Soo Kim
Journal:  J Pharmacopuncture       Date:  2018-09-30
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.